Summit Therapetuics shares skyrocketed Tuesday on word that it has entered into an exclusive licensing agreement with drugmaker Sarepta Therapeutics . The two companies will develop drugs to treat Duchenne muscular dystrophy. Under the agreement, Summit will get $40 million up front and could receive $522 million in milestone payments. Just last month, Sarepta won approval from the FDA for a drug to treat the disorder.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
